**Author details**

Suzanne Pruijssers\*, Ernst van Heurn and Nicole Bouvy Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands

\*Address all correspondence to: s.pruijssers@maastrichtuniversity.nl

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**49**

*Endoluminal Techniques to Treat Obesity DOI: http://dx.doi.org/10.5772/intechopen.82733*

[1] WHO. Obesity and Overweight Factsheet. 2018. Available from: http:// www.who.int/news-room/fact-sheets/

with obesity: A meta-analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care.

[9] Ryder REJ, Munro L, Mcmaster JJ, Bessell J, Bascomb JM, Collins JE, et al. First risk-benefit data from the worldwide endobarrier registry. Diabetes. 2018;**67**(Supplement 1)

[10] Forner PM, Ramacciotti T, Farey JE, Lord RV. Safety and effectiveness of an endoscopically placed duodenaljejunal bypass device (EndoBarrier(R)): Outcomes in 114 patients. Obesity Surgery. 2017;**27**(12):3306-3313

[11] Quezada N, Munoz R, Morelli C, Turiel D, Hernandez J, Pimentel F, et al. Safety and efficacy of the endoscopic duodenal-jejunal bypass liner prototype in severe or morbidly obese subjects implanted for up to 3 years. Surgical Endoscopy. 2018;**32**(1):260-267

[12] Sandler BJ, Rumbaut R, Swain CP, Torres G, Morales L, Gonzales L, et al. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surgical Endoscopy.

[13] Sandler BJ, Rumbaut R, Swain CP, Torres G, Morales L, Gonzales L, et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surgical Endoscopy. 2015;**29**(11):3298-3303

[14] Moreno C, Closset J, Dugardeyn S, Barea M, Mehdi A, Collignon L, et al. Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese patients: Results of the second human pilot study. Endoscopy.

[15] Deviere J, Ojeda Valdes G, Cuevas Herrera L, Closset J, Le Moine O,

Eisendrath P, et al. Safety, feasibility and

2011;**25**(9):3028-3033

2008;**40**(5):406-413

2018;**41**(5):1106-1115

[2] Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative

[3] Sjostrom L. Bariatric surgery and reduction in morbidity and mortality: Experiences from the SOS study. International Journal of Obesity. 2008;**32**(Suppl 7):S93-S97

[4] Ruban A, Ashrafian H, Teare JP. The EndoBarrier: Duodenal-jejunal bypass liner for diabetes and weight loss. Gastroenterology Research and Practice.

[5] Patel N, Mohanaruban A, Ashrafian H, Le Roux C, Byrne J, Mason J, et al. EndoBarrier(R): A safe and effective novel treatment for obesity and type 2 diabetes? Obesity Surgery.

[6] Schouten R, Rijs CS, Bouvy ND, Hameeteman W, Koek GH, Janssen IM, et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Annals of Surgery. 2010;**251**(2):236-243

[7] Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Annals of Surgery. 2014;**260**(6):984-992

[8] Jirapinyo P, Haas AV, Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes

2018;**2018**:7823182

2018;**28**(7):1980-1989

detail/obesity-and-overweight

studies of bariatric surgery vs conventional medical therapy: A systematic review and meta-analysis. Obesity Surgery. 2014;**24**(3):437-455

**References**

*Endoluminal Techniques to Treat Obesity DOI: http://dx.doi.org/10.5772/intechopen.82733*
